Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
The Era of Vaccines: Advancing Tumor Immunology and Immunotherapy
share announcement

The Era of Vaccines: Advancing Tumor Immunology and Immunotherapy

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccination Against Cancer and Chronic Diseases".

Deadline for manuscript submissions: 30 November 2026 | Viewed by 1492

Special Issue Editors

Dr. Surendra Shukla

E-Mail Website
Guest Editor
Department of Oncology Science, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Interests: designing novel therapeutic strategy to overcome therapy resistance in different types of cancers; exploring the molecular mechanism of therapeutic resistance in gastrointestinal cancers
Special Issues, Collections and Topics in MDPI journals
Dr. Vinay Kumar

E-Mail Website
Guest Editor
College of Medicine, The Pennsylvania State University Hershey Medical Center, Hershey, PA 17033, USA
Interests: cardiovascular disease; human disease; physiology and cell biology, immunotherapy; drug discovery; molecular biology; genetic engineering
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We invite you to submit to our Special Issue titled “The Era of Vaccines: Advancing Tumor Immunology and Immunotherapy”. The complex interactions between the immune system and cancer have become a vital area of study in oncology, leading to significant advancements in tumor immunology and immunotherapy. We seek articles that explore the mechanisms that regulate immune responses within the tumor microenvironment, innovative immunotherapeutic treatments, and translational methods to improve cancer treatment outcomes. The Special Issue will include advancements in neoantigen-based vaccines, dendritic cell vaccines, mRNA vaccines, peptide-based approaches, and combination therapies. We welcome research articles, reviews, and novel methodologies that cover key topics such as cancer vaccines and immunotherapy, tumor immune evasion, immune checkpoint blockade therapy, mechanisms of resistance, CAR-T, T and NK cell therapies, biomarkers, and immunotherapy.

Dr. Surendra Shukla
Dr. Vinay Kumar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer immunotherapy
  • tumor microenvironment
  • immune editing
  • immune checkpoints, CAR-T and NK therapy
  • biomarkers for immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 420 KB  
Article
Feasibility and Safety of Autologous Dendritic Cell Vaccination Combined with Radio-Chemotherapy in Newly Diagnosed Glioblastoma: A Retrospective Single-Center Series
by Inés Esparragosa Vázquez, Ascensión López-Díaz de Cerio, Susana Inoges, Javier Aristu, Pablo Domínguez, Reyes García-Eulate, Marta Calvo-Imirizaldu, Javier Arbizu, María E. Rodríguez-Ruiz, Pablo Irimia, Marta M. Alonso, Felipe Prósper, Ricardo Díez-Valle and Jaime Gállego Pérez-Larraya
Vaccines 2026, 14(2), 172; https://doi.org/10.3390/vaccines14020172 - 12 Feb 2026
Viewed by 977
Abstract
Background: The prognosis of glioblastoma (GBM) patients remains poor. Dendritic cell (DC) vaccination has been investigated as an immunotherapy option, mainly in early-phase clinical studies. Herein, we report the feasibility, safety, and descriptive clinical and radiological outcomes of a retrospective series of newly [...] Read more.
Background: The prognosis of glioblastoma (GBM) patients remains poor. Dendritic cell (DC) vaccination has been investigated as an immunotherapy option, mainly in early-phase clinical studies. Herein, we report the feasibility, safety, and descriptive clinical and radiological outcomes of a retrospective series of newly diagnosed GBM patients treated with standard radio-chemotherapy and autologous DC vaccination as compassionate use. Methods: We retrospectively reviewed the medical and radiological records of patients with newly diagnosed GBM who received autologous tumor lysate–pulsed DC vaccination in addition to standard-of-care treatment at a tertiary academic center between 2009 and 2017. Clinical data, treatment characteristics, adverse events, survival outcomes, and radiological responses were collected and analyzed descriptively. Results: Twenty-four patients were included. All patients underwent surgical resection and were further treated with autologous tumor lysate–DC vaccination and standard radio-chemotherapy. Histology of GBM was confirmed in all patients. The first vaccine was administered in 75% of patients after a median of 21 days (range: 6–30 days) following surgery and prior to radiotherapy initiation. DC vaccination was continued following radiotherapy at specific time points, with no observed significant adverse events. Median OS was 21.1 months (95% CI, 27.9–75.0 months), and median PFS was 10.3 months (95% CI, 15.6–26.6 months). Presence of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation was associated with longer survival and higher 12-month PFS rates, consistent with its established prognostic value. Radiological responses were retrospectively assessed according to RANO and RANO 2.0 criteria. Conclusions: In this retrospective single-center series, autologous DC vaccination administered as compassionate use in combination with standard radio-chemotherapy was feasible and safe in routine clinical practice. Survival and radiological outcomes are reported descriptively and should be interpreted with caution given the absence of a control cohort. These findings support further prospective controlled studies to properly assess the clinical role of DC vaccination in newly diagnosed GBM. Full article
(This article belongs to the Special Issue The Era of Vaccines: Advancing Tumor Immunology and Immunotherapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop